Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity

被引:30
作者
Jismy, Badr [1 ]
El Qami, Abdelkarim [2 ]
Pislar, Anja [3 ]
Frlan, Rok [3 ]
Kos, Janko [3 ,4 ]
Gobec, Stanislav [3 ]
Knez, Damijan [3 ]
Abarbri, Mohamed [1 ]
机构
[1] Fac Sci, Lab Phys Chim Mat & Electrolytes Energie PCM2E2, EA 6299, Ave Monge,Parc Grandmont, F-37200 Tours, France
[2] Univ Hassan II Casablanca, Dept Chim, Lab Chim Phys & Chim Bioorgan, URAC 22, BP 146, Mohammadia 28800, Morocco
[3] Univ Ljubljana, Fac Pharm, Askerceva 7, SI-1000 Ljubljana, Slovenia
[4] Jozef Stefan Inst, Dept Biotechnol, Jamova 39, SI-1000 Ljubljana, Slovenia
关键词
Monoamine oxidase; Parkinson's disease; Neuroprotection; Pyrimido[1,2-b]indazoles; Inhibitors; CROSS-COUPLING REACTIONS; MAO INHIBITORS; DIRECT ACCESS; EFFICIENT; 3-AMINOINDAZOLES; SCAFFOLDS; DISCOVERY; DISEASE; AGENTS;
D O I
10.1016/j.ejmech.2020.112911
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Structurally diverse heterotricyclic compounds are recognized as monoamine oxidase (MAO) inhibitors and thus represent an appealing scaffold in development and optimization of novel MAO inhibitors. Herein we explored the chemical space of pyrimido[1,2-b]indazoles as MAO inhibitors by preparing a small library of (hetero)aryl derivatives. An efficient synthetic strategy was developed starting from commercially available 1H-indazol-3-amines, which were converted to various 3-bromoheterotricyclic derivatives and further functionalized via Suzuki-Miyaura coupling reaction. Derivatives 4a-t selectively inhibited human MAO-B isoform in a reversible and competitive manner as confirmed by kinetic experiments and docking studies. Selected derivatives were not cytotoxic to neuroblastoma SH-SY5Y cells. Moreover, analogue 4i protected human neuroblastoma SH-SY5Y cells against 6-hydroxydopamine-induced cell death, which confirms the applicability of the pyrimido[1,2-b]indazoles as potential antiparkinsonian agents. (C) 2020 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:16
相关论文
共 57 条
  • [1] The epidemiology of Parkinson's disease: risk factors and prevention
    Ascherio, Alberto
    Schwarzschild, Michael A.
    [J]. LANCET NEUROLOGY, 2016, 15 (12) : 1255 - 1270
  • [2] An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds via GBB reaction
    Balwe, Sandip Gangadhar
    Jeong, Yeon Tae
    [J]. ORGANIC & BIOMOLECULAR CHEMISTRY, 2018, 16 (08) : 1287 - 1296
  • [3] Green synthesis and characterization of silver nanoparticles (Ag NPs) from extract of plant Radix Puerariae: An efficient and recyclable catalyst for the construction of pyrimido [1,2-b] indazole derivatives under solvent-free conditions
    Balwe, Sandip Gangadhar
    Shinde, Vijay Vilas
    Rokade, Ashish A.
    Park, Seong Soo
    Jeong, Yeon Tae
    [J]. CATALYSIS COMMUNICATIONS, 2017, 99 : 121 - 126
  • [4] DockRMSD: an open-source tool for atom mapping and RMSD calculation of symmetric molecules through graph isomorphism
    Bell, Eric W.
    Zhang, Yang
    [J]. JOURNAL OF CHEMINFORMATICS, 2019, 11 (1)
  • [5] Palladium catalysts for the Suzuki cross-coupling reaction: An overview of recent advances
    Bellina, F
    Carpita, A
    Rossi, R
    [J]. SYNTHESIS-STUTTGART, 2004, (15): : 2419 - 2440
  • [6] Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives
    Carotti, Andrea
    Catto, Marco
    Leonetti, Francesco
    Campagna, Francesco
    Soto-Otero, Ramon
    Mendez-Alvarez, Estefania
    Thull, Ulrike
    Testa, Bernard
    Altomare, Cosimo
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (22) : 5364 - 5371
  • [7] MAO inhibitors and their wider applications: a patent review
    Carradori, Simone
    Secci, Daniela
    Petzer, Jacques P.
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2018, 28 (03) : 211 - 226
  • [8] Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients
    Cattaneo, Carlo
    Jost, Wolfgang H.
    Bonizzoni, Erminio
    [J]. JOURNAL OF PARKINSONS DISEASE, 2020, 10 (01) : 89 - 97
  • [9] Polypharmacy in Parkinson's disease: risks and benefits with little evidence
    Csoti, I.
    Herbst, H.
    Urban, P.
    Woitalla, D.
    Wuellner, U.
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2019, 126 (07) : 871 - 878
  • [10] SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
    Daina, Antoine
    Michielin, Olivier
    Zoete, Vincent
    [J]. SCIENTIFIC REPORTS, 2017, 7